research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Sorafenib-induced Facial Acneiform Eruption
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
research Pathogenesis and management of TRPV3-related Olmsted syndrome
EGFR and mTOR inhibitors may help manage Olmsted syndrome symptoms.
research Diffuse Alopecia in a Hemodialysis Patient Caused by a Low-Molecular-Weight Heparin, Tinzaparin
A hemodialysis patient's hair loss was caused by the drug tinzaparin but stopped after switching to a different drug.
research Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study
Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
research Minoxidil-Induced Pleuro-Pericardial Effusion With Tamponade
Stopping minoxidil and draining fluid around the heart can save lives in rare cases.
research Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
research ALOPECIA TEMPORÁRIA APÓS TRATAMENTO ENDOVASCULAR RELACIONADA A UMA MALFORMAÇÃO ARTERIOVENOSA EM FACE: RELATO DE CASO
Onyx® embolization effectively treats facial arteriovenous malformations with minimal complications.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
Selumetinib causes fewer and less severe skin issues in children than binimetinib.
research LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research Methotrexate/tacrolimus/voriconazole
A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
research Sequential Immunotherapy with Tofacitinib and Low-Dose IL-2 Induces Sustained Remission in Alopecia Areata: A Proof-of-concept monocentric study
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes
Ozenoxacin reduces sebum production, helping manage acne.
research RASopathic Skin Eruptions during Vemurafenib Therapy
Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Comparative Efficacy and Adverse Clinical Events of Methotrexate versus Azathioprine with Steroid Mini Pulse Therapy in the Management of Moderate to Severe Alopecia Areata: A Tertiary Centre Based Interventional Study
Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
research Excimer Light versus Combination of Tacrolimus and Excimer Light in the Treatment of Alopecia Areata
Combining tacrolimus with excimer light is more effective for treating alopecia areata than using excimer light alone.
research HDL as Therapeutic Tools
Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.
research Minoxidil prevents 3,4-methylenedioxymethamphetamine-induced serotonin depletions: role of mitochondrial ATP-sensitive potassium channels, Akt and ERK
Minoxidil prevents serotonin loss from MDMA by affecting potassium channels and increasing Akt phosphorylation.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine
Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.